<table id="ID956" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 9: Drugs That are Affected by and Affecting Ciprofloxacin</caption>
<col width="23%"></col>
<col width="30%"></col>
<col width="47%"></col>
<tbody>
<tr>
<td align="center" colspan="3" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Drugs </content>
<content stylecode="bold">That </content>
<content stylecode="bold">are </content>
<content stylecode="bold">Affected </content>
<content stylecode="bold">by </content>
<content stylecode="bold">Ciprofloxacin </content>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Drug</content>
<content stylecode="bold">(</content>
<content stylecode="bold">s</content>
<content stylecode="bold">) </content>
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Recommendation</content>
<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Comments</content>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Tizanidine <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Contraindicated<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Concomitant administration of tizanidine and  ciprofloxacin is contraindicated due to the  potentiation of hypotensive and sedative effects of  tizanidine [see CONTRAINDICATIONS (<linkhtml href="#ID892">4.2</linkhtml>)]  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Theophylline <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Avoid Use <br/>(Plasma Exposure Likely to be <br/>Increased and Prolonged)<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Concurrent administration of ciprofloxacin with  theophylline may result in increased risk of a patient  developing central nervous system (CNS) or other  adverse reactions. If concomitant use cannot be  avoided, monitor serum levels of theophylline and  adjust dosage as appropriate [see WARNINGS AND  PRECAUTIONS (<linkhtml href="#ID916">5.9</linkhtml>)].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Drugs Known to Prolong QT Interval <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Avoid Use<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Ciprofloxacin may further prolong the QT interval in  patients receiving drugs known to prolong the QT  interval (for example, class IA or III antiarrhythmics,  tricyclic antidepressants, macrolides, antipsychotics)  [see WARNINGS AND PRECAUTIONS  (<linkhtml href="#ID920">5.11</linkhtml>) and USE IN SPECIFIC  POPULATIONS (<linkhtml href="#ID967">8.5</linkhtml>)]. </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Oral antidiabetic drugs <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Use with caution Glucose-lowering <br/>effect potentiated<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Hypoglycemia sometimes severe has been reported  when ciprofloxacin and oral antidiabetic agents,  mainly sulfonylureas (for example, glyburide,  glimepiride), were co-administered, presumably by  intensifying the action of the oral antidiabetic agent.  Fatalities have been reported. Monitor blood glucose  when ciprofloxacin is co-administered with oral  antidiabetic drugs [see ADVERSE REACTIONS (<linkhtml href="#ID940">6.1</linkhtml>)].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Phenytoin <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Use with caution <br/>Altered serum levels of <br/>phenytoin (increased and <br/>decreased)<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">To avoid the loss of seizure control associated with <br/>decreased phenytoin levels and to prevent phenytoin <br/>overdose-related adverse reactions upon <br/>ciprofloxacin discontinuation in patients receiving <br/>both agents, monitor phenytoin therapy, including <br/>phenytoin serum concentration during and shortly <br/>after co-administration of ciprofloxacin with phenytoin. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Cyclosporine <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Use with caution <br/>(transient elevations in serum <br/>creatinine)<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Monitor renal function (in particular serum <br/>creatinine) when ciprofloxacin is co-administered <br/>with cyclosporine. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Anti-coagulant drugs <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Use with caution <br/>(Increase in anticoagulant <br/>effect)<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">The risk may vary with the underlying infection, age <br/>and general status of the patient so that the <br/>contribution of ciprofloxacin to the increase in INR <br/>(international normalized ratio) is difficult to assess. <br/>Monitor prothrombin time and INR frequently during <br/>and shortly after co-administration of ciprofloxacin <br/>with an oral anti-coagulant (for example, warfarin). <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Methotrexate <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Use with caution <br/>Inhibition of methotrexate renal <br/>tubular transport potentially <br/>leading to increased <br/>methotrexate plasma levels<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Potential increase in the risk of methotrexate <br/>associated toxic reactions. Therefore, carefully <br/>monitor patients under methotrexate therapy when <br/>concomitant ciprofloxacin therapy is indicated. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Ropinirole <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Use with caution<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Monitoring for ropinirole-related adverse reactions  and appropriate dose adjustment of ropinirole is  recommended during and shortly after co- administration with ciprofloxacin [see WARNINGS  AND PRECAUTIONS (<linkhtml href="#ID930">5.16</linkhtml>)].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Clozapine <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Use with caution<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Careful monitoring of clozapine associated adverse <br/>reactions and appropriate adjustment of clozapine <br/>dosage during and shortly after co-administration <br/>with ciprofloxacin are advised. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">NSAIDs <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Use with caution<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Non-steroidal anti-inflammatory drugs (but not acetyl <br/>salicylic acid) in combination of very high doses of <br/>quinolones have been shown to provoke convulsions <br/>in pre-clinical studies and in postmarketing. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Sildenafil <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Use with caution Two-fold increase in exposure<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Monitor for sildenafil toxicity [see CLINICAL  PHARMACOLOGY <linkhtml href="#ID983">12.3</linkhtml>].  </td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Duloxetine <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Avoid Use<br/>Five-fold increase in duloxetine exposure<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">If unavoidable, monitor for duloxetine toxicity <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Caffeine/Xanthine <br/>Derivatives <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Use with caution<br/>Reduced clearance resulting in <br/>elevated levels and prolongation <br/>of serum half-life<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Ciprofloxacin inhibits the formation of paraxanthine <br/>after caffeine administration (or pentoxifylline <br/>containing products). Monitor for xanthine toxicity <br/>and adjust dose as necessary. <br/>
</td>
</tr>
<tr>
<td align="center" colspan="3" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Drug</content>
<content stylecode="bold">(</content>
<content stylecode="bold">s</content>
<content stylecode="bold">) </content>
<content stylecode="bold">Affecting </content>
<content stylecode="bold">Pharmacokinetics </content>
<content stylecode="bold">of </content>
<content stylecode="bold">Ciprofloxacin</content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Antacids, Sucralfate, Multivitamins and Other Products <br/>Containing Multivalent Cations (magnesium/aluminum <br/>antacids; polymeric phosphate binders (for example, <br/>sevelamer, lanthanum carbonate); sucralfate; Videx<sup>®</sup> <br/>(didanosine) chewable/buffered tablets or pediatric powder; <br/>other highly buffered drugs; or products containing <br/>calcium, iron, or zinc and dairy products) <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Ciprofloxacin should be taken at  least two hours before or six  hours after Multivalent cation- containing products  administration [see DOSAGE  AND ADMINISTRATION (<linkhtml href="#ID866">2.4</linkhtml>)]. </td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Decrease ciprofloxacin absorption, resulting in lower <br/>serum and urine levels <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Probenecid <br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Use with caution (interferes <br/>with renal tubular secretion of <br/>ciprofloxacin and increases <br/>ciprofloxacin serum levels)<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">Potentiation of ciprofloxacin toxicity may occur. <br/>
</td>
</tr>
</tbody>
</table>